Evidence map›Paper›PMID 33499881›Full record

ReviewCancer cell international2021

Targeting androgen receptor signaling with MicroRNAs and Curcumin: a promising therapeutic approach for Prostate Cancer Prevention and intervention.

Zeeshan Javed, Khushbukhat Khan, Amna Rasheed, Haleema Sadia, Muhammad Naeem Shahwani, Asma Irshad, Shahid Raza, Bahare Salehi, Javad Sharifi-Rad, Hafiz A R Suleria and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 7 countries.

Zeeshan Javed *Office for Research Innovation and Commercialization, Lahore Garrison University, DHA, Sector-C, Phase VI, Lahore, Pakistan.
Khushbukhat Khan *Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), 44000, Islamabad, Pakistan.
Amna RasheedSchool of Basic Medical Sciences, Lanzhou University, 730000, Lanzhou, PR China.
Haleema SadiaDepartment of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences, Quetta, Pakistan.
Muhammad Naeem ShahwaniDepartment of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences, Quetta, Pakistan.
Asma IrshadDepartment of Life Sciences, University of Management Sciences, Lahore, Pakistan.
Shahid RazaOffice for Research Innovation and Commercialization, Lahore Garrison University, DHA, Sector-C, Phase VI, Lahore, Pakistan.
Bahare SalehiMedical Ethics and Law Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. bahar.salehi007@gmail.com.
Javad Sharifi-RadPhytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. javad.sharifirad@gmail.com.ORCID http://orcid.org/0000-0002-7301-8151
Hafiz A R SuleriaSchool of Agriculture and Food, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, 3010, Parkville, VIC, Australia.
Natália Cruz-MartinsFaculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. ncmartins@med.up.pt.
Cristina QuispeFacultad de Ciencias de la Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, 1110939, Iquique, Chile. elquispe@unap.cl.
Balochistan University of Information Technology, Engineering and Management Sciences · PKLahore Garrison University · PKArturo Prat University · CLLahore University of Management Sciences · PKLanzhou University · CNNational University of Sciences and Technology · PKShahid Beheshti University of Medical Sciences · IRThe University of Melbourne · AUUniversidad del Azuay · ECUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PC) is a multifactorial disease characterized by the abrogation of androgen receptor signaling. Advancement in microbiology techniques has highlighted the significant role of microRNAs (miRNAs) in the progression of PC cells from an androgen-dependent to an androgen-independent state. At that stage, prostate tumors also fail to respond to currently practiced hormone therapies. So, studies in recent decades are focused on investigating the anti-tumor effects of natural compounds in PC. Curcumin is widely recognized and now of huge prestige for its anti-proliferative abilities in different types of cancer. However, its limited solubility, compatibility, and instability in the aqueous phase are major hurdles when administering. Nanoformulations have proven to be an excellent drug delivery system for various drugs and can be used as potential delivery platforms for curcumin in PC. In this review, a shed light is given on the miRNAs-mediated regulation of androgen receptor (AR) signaling and miRNA-curcumin interplay in PC, as well as on curcumin-based nanoformulations that can be used as possible therapeutic solutions for PC.

Indexed as

Androgen receptor signalingCurcuminDiagnostic markersMicroRNAsNanoformulationsProstate cancer

Identifiers

PMID33499881
PMCPMC7836194
OpenAlexW3125231859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.